PepGen Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
PepGen's DSMB recommended advancing PGN-EDODM1 into the 12.5 mg/kg cohort of Phase 2 FREEDOM2-DM1 trial (highest planned dose) with no protocol changes. The 10 mg/kg cohort is fully enrolled with 7 of 8 participants completing dosing; data expected November 2026. The 12.5 mg/kg cohort results are expected in H1 2027. The company has $117.2M in cash as of June 30, 2026, sufficient to fund operations into Q4 2027. Q2 2026 net loss was $17.8M ($0.26/share) on 69.3M shares outstanding, improved from $23.1M loss in Q2 2025.
Why this rating
Dose escalation approval with favorable safety data supports program advancement; $117M runway covers ~18 months but clinical-stage company with single asset. Meaningful for company trajectory.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.